Newswise Feature Channel: ASCO Meeting News

Breakthroughs in Breast Cancer: Susan G. Komen(R) Scholars and Studies Highlighted at ASCO 2024

Susan G. Komen — Thu, 06 Jun 2024 10:05:11 EST

Scholars and studies funded by Susan G. Komen(R), the world's leading breast cancer organization, showcased cutting-edge breast cancer research aimed at advancing the field at the ASCO Annual Meeting 2024. Organized by the American Society of Clinical Oncology, this premier conference annually convenes over 40,000 oncologists and stakeholders worldwide.

AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024

AbelZeta Pharma, Inc. — Tue, 04 Jun 2024 08:05:25 EST

CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4

ASCO: New 'Armored' CAR produces significant responses in patients whose cancers don't respond to current CAR T cell therapies

Perelman School of Medicine at the University of Pennsylvania — Sat, 01 Jun 2024 16:00:00 EST

A new "armored" form of CAR T cell therapy may be able to help patients with non-Hodgkin lymphoma whose cancers do not respond to currently available CAR T cell therapies. The Phase I clinical trial was presented at the 2024 ASCO Annual Meeting.

Multicancer detection tests, AI prediction tools for cancer among research topics presented by Ohio State at ASCO 2024

Ohio State University Wexner Medical Center — Sat, 01 Jun 2024 13:05:50 EST

How artificial intelligence tools could help predict colon cancer aggressiveness and how the gut microbiome might provide clues to the rapid rise in colon cancers among young people are among dozens of research studies being presented by The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) at the 2024 American Society of Clinical Oncology annual meeting, which takes place May 31 through June 4 in Chicago, Illinois. Among other emerging health topics being discussed are the use of multicancer screening tests and how equity should be a critical point of consideration in the commercial development of these tools.

Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma

Dana-Farber Cancer Institute — Sat, 01 Jun 2024 08:05:56 EST

Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.

ASCO: Novel CAR T therapy and shorter targeted therapy durations show promise for patients with leukemia

University of Texas MD Anderson Cancer Center — Fri, 31 May 2024 14:45:00 EST

Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

ASCO 2024: UChicago Medicine cancer experts available for interviews

University of Chicago Medical Center — Thu, 30 May 2024 17:05:40 EST

Study Reveals Worse Clinical Outcomes in Breast Cancer Patients Who Reported Higher Pain and Stress

Roswell Park Comprehensive Cancer Center — Thu, 30 May 2024 16:25:45 EST

Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).

Study Shows Polygenic Risk Score (PGS) Could Predict Breast Cancer Survival Outcomes

Roswell Park Comprehensive Cancer Center — Thu, 30 May 2024 16:00:28 EST

Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.

Promising New Treatment for Patients with HR+ HER-2 Negative Metastatic Breast Cancer

Yale Cancer Center/Smilow Cancer Hospital — Thu, 30 May 2024 15:05:56 EST

New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer.

Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): results from a multi-center Phase II trial

UT Southwestern Medical Center — Wed, 29 May 2024 21:05:50 EST

ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).

Yale Cancer Center/Smilow Cancer Hospital — Wed, 29 May 2024 21:05:40 EST

A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer.

Yale Cancer Center/Smilow Cancer Hospital — Wed, 29 May 2024 21:05:37 EST

ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.

Yale Cancer Center/Smilow Cancer Hospital — Wed, 29 May 2024 21:05:23 EST

Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC)

UT Southwestern Medical Center — Wed, 29 May 2024 21:05:16 EST

Fibrolamellar hepatocellular carcinoma (FL-HCC) epidemiology, survival characteristics, and outcomes: Surveillance, epidemiology, and end results database (SEER) study

Corewell Health — Wed, 29 May 2024 18:05:47 EST

Association between congenital heart disease and cancer: A meta-analysis of 30 million patients

Corewell Health — Wed, 29 May 2024 18:05:46 EST

Clinically significant variant classification resulting from the addition of RNA sequencing: Experience at high-volume cancer genetics center

Corewell Health — Wed, 29 May 2024 18:05:44 EST

Cancer screening in sexual and gender minority populations: A systematic review and meta-analysis

Corewell Health — Wed, 29 May 2024 18:05:43 EST

Non-Hodgkin lymphoma mortality disparities across different sexes, races, and geographic locations

Corewell Health — Wed, 29 May 2024 18:05:42 EST